Infantile fibrosarcoma (IFS) is an extremely rare locally aggressive soft tissue tumour of childhood. Primary therapy involves complete surgical resection with or without chemotherapy. However complete surgical resection might not be feasible in all cases and so requires other modalities for further management. We report the case of a male infant from Bangladesh with a locally advanced IFS of the leg which was partially resected. The patient received adjuvant chemotherapy which was complicated by the development of chemotherapy-related veno-occlusive disease and had to be discontinued. Thereafter he was referred to our dedicated sarcoma oncology clinic in India for further management. The parents of the child refused amputation of the limb. The tumour tested positive for NTRK3-ETV6 gene fusion and after discussion in multidisciplinary clinic, targeted therapy using oral NTRK inhibitor larotrectinib was started. The patient had complete response at the end of 8 months of treatment with larotrectinib. This is the first report from the Indian subcontinent and we encourage that these children should be referred to specialist clinics for appropriate multidisciplinary management for best outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393313PMC
http://dx.doi.org/10.3332/ecancer.2023.1575DOI Listing

Publication Analysis

Top Keywords

infantile fibrosarcoma
8
inhibitor larotrectinib
8
complete surgical
8
surgical resection
8
limb salvage
4
salvage infant
4
infant infantile
4
fibrosarcoma trk
4
trk inhibitor
4
larotrectinib infantile
4

Similar Publications

Background: Infantile fibrosarcoma (IFS) is a rare pediatric tumor of intermediate malignancy with high local aggressiveness that typically presents in young infants. Its occurrence in the head and neck region is rare. Complete non-mutilating surgical resection is often not possible, requiring multimodal treatment.

View Article and Find Full Text PDF

NTRK (neurotropic tropomyosin receptor kinase)-rearranged spindle cell tumours represent a rare group of molecularly defined soft tissue neoplasms. These tumours, excluding infantile fibrosarcomas, are characterised by NTRK gene rearrangements and exhibit a range of histomorphologies, including spindle, epithelioid or rhabdoid cells with invasive growth. Their prognosis correlates with histological grade, and surgical resection is the primary treatment.

View Article and Find Full Text PDF

Purpose: The TRK inhibitor larotrectinib is US Food and Drug Administration approved for fusion-positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed fusion-positive solid tumors with response-adapted duration of therapy and local control.

Methods: Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability.

View Article and Find Full Text PDF
Article Synopsis
  • - Congenital peribronchial myofibroblastic tumor (CPMT) is a rare benign tumor found in infants, identified by unique histological features, including cartilaginous islands and spindle cells, which can lead to serious complications despite its benign classification.
  • - Genetic analysis reveals that a specific alteration, the EGFR kinase domain duplication (KDD), is a common oncogenic driver in CPMT cases, suggesting that CPMT and similar tumors, like congenital mesoblastic nephromas, may share underlying molecular mechanisms and be related.
  • - Following surgical resection of the tumors, patients demonstrated varied outcomes; while one patient died shortly after surgery, the remaining three were free of recurrence, indicating
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!